** Shares of biotech firm Protara Therapeutics TARA.O rise 50% to $5.32 premarket
** Co says its experimental cell therapy to treat a type of bladder cancer helped remove all signs of cancer in 72% of patients at six months of treatment in an open-label mid-stage study
** The therapy, TARA-002, showed a favorable safety and tolerability profile and no patients discontinued due to side-effects - TARA
** TARA-002 is being developed to treat high-risk non-muscle invasive bladder cancer (NMIBC)
** Bladder cancer is the sixth most common cancer in the United States, with NMIBC representing ~80% of bladder cancer diagnoses -TARA
** Up to last close, stock up ~89% YTD
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。